Impact of Preoperative Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios on Long-Term Survival in Patients with Operable Pancreatic Ductal Adenocarcinoma.


Journal

Medical principles and practice : international journal of the Kuwait University, Health Science Centre
ISSN: 1423-0151
Titre abrégé: Med Princ Pract
Pays: Switzerland
ID NLM: 8901334

Informations de publication

Date de publication:
2022
Historique:
received: 30 03 2022
accepted: 02 10 2022
pubmed: 3 11 2022
medline: 7 1 2023
entrez: 2 11 2022
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. The outcomes of patients with cancer are determined not only by tumor-related factors but also by systemic inflammatory response. The objective of the study was to identify whether the preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are associated with the prognosis of PDAC of the pancreas head after curative pancreatoduodenectomy. Seventy-six patients were enrolled in this prospective, observational clinical study. The optimal NLR and PLR cut-off values were calculated using a receiver operating characteristic (ROC) curve analysis. ROC curve analysis revealed an optimal NLR and PLR cut-off point of 5.41 and 205.56, respectively. Consequently, the NLR and PRL scores were classified as NLR <5.41 or ≥5.41 and PLR <205.56 or ≥205.56. The clinical outcomes of overall survival (OS) and disease-free survival (DFS) were calculated by Kaplan-Meier survival curves. Univariate and multivariate analyses were performed to analyze the prognostic value of NLR and PLR. Low preoperative NLR and PLR levels both correlated with better pathological features, including decreased depth of invasion (p < 0.001), less lymph node metastasis (p < 0.001), earlier stage (p < 0.001), and lymphovascular invasion (p = 0.004). Kaplan-Meier plots illustrated that higher preoperative NLR and PLR had does not influence OS and DFS. Univariate analysis revealed that depth of invasion, lymph node metastasis, stage, PLR, and NLR are risk factors affecting OS and DFS. Multivariate analysis revealed that only stage was independently associated with OS and DFS. NLR and PLR measurements cannot provide important prognostic results in patients with resectable PDAC.

Sections du résumé

BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. The outcomes of patients with cancer are determined not only by tumor-related factors but also by systemic inflammatory response. The objective of the study was to identify whether the preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are associated with the prognosis of PDAC of the pancreas head after curative pancreatoduodenectomy.
MATERIALS AND METHODS
Seventy-six patients were enrolled in this prospective, observational clinical study. The optimal NLR and PLR cut-off values were calculated using a receiver operating characteristic (ROC) curve analysis. ROC curve analysis revealed an optimal NLR and PLR cut-off point of 5.41 and 205.56, respectively. Consequently, the NLR and PRL scores were classified as NLR <5.41 or ≥5.41 and PLR <205.56 or ≥205.56. The clinical outcomes of overall survival (OS) and disease-free survival (DFS) were calculated by Kaplan-Meier survival curves. Univariate and multivariate analyses were performed to analyze the prognostic value of NLR and PLR.
RESULTS
Low preoperative NLR and PLR levels both correlated with better pathological features, including decreased depth of invasion (p < 0.001), less lymph node metastasis (p < 0.001), earlier stage (p < 0.001), and lymphovascular invasion (p = 0.004). Kaplan-Meier plots illustrated that higher preoperative NLR and PLR had does not influence OS and DFS. Univariate analysis revealed that depth of invasion, lymph node metastasis, stage, PLR, and NLR are risk factors affecting OS and DFS. Multivariate analysis revealed that only stage was independently associated with OS and DFS.
CONCLUSIONS
NLR and PLR measurements cannot provide important prognostic results in patients with resectable PDAC.

Identifiants

pubmed: 36323225
pii: 000527360
doi: 10.1159/000527360
pmc: PMC9841763
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

586-594

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Références

Int J Surg Case Rep. 2020;77S:S17-S20
pubmed: 33168455
Sci Rep. 2017 Apr 9;7(1):753
pubmed: 28392554
Ann Surg. 2017 Jan;265(1):185-191
pubmed: 27163957
Pancreatology. 2016 May-Jun;16(3):434-40
pubmed: 26852169
Am J Surg. 2009 Apr;197(4):466-72
pubmed: 18639229
Pancreatology. 2017 Sep - Oct;17(5):839-846
pubmed: 28803860
Br J Cancer. 2013 Jul 23;109(2):416-21
pubmed: 23799847
Future Oncol. 2010 Jan;6(1):149-63
pubmed: 20021215
World J Surg Oncol. 2017 May 30;15(1):108
pubmed: 28558772
Am J Clin Oncol. 2018 Mar;41(3):242-247
pubmed: 26757436
World J Surg. 2008 Jun;32(6):1051-6
pubmed: 18224462
Surg Oncol. 2022 Aug;43:101791
pubmed: 35716547
Hepatogastroenterology. 2010 May-Jun;57(99-100):640-5
pubmed: 20698242
Curr Med Res Opin. 2018 May;34(5):857-863
pubmed: 29161926
World J Surg. 2017 Oct;41(10):2619-2624
pubmed: 28439647
Clin Case Rep. 2020 Sep 10;8(11):2111-2115
pubmed: 33235738
Minerva Gastroenterol Dietol. 2020 Sep;66(3):290-291
pubmed: 32272821
Ann Surg Oncol. 2015 Dec;22(13):4363-70
pubmed: 25805235
Ann Med Surg (Lond). 2019 Jul 09;44:79-82
pubmed: 31341616
Exp Ther Med. 2012 Mar;3(3):423-432
pubmed: 22969906
Onco Targets Ther. 2018 Apr 05;11:1899-1908
pubmed: 29670365
Eur Rev Med Pharmacol Sci. 2021 May;25(10):3670-3678
pubmed: 34109576
Hepatogastroenterology. 2001 Sep-Oct;48(41):1493-8
pubmed: 11677994
J Clin Oncol. 2010 Sep 10;28(26):4045-51
pubmed: 20644090
J Thromb Haemost. 2011 Feb;9(2):237-49
pubmed: 21040448
J Clin Oncol. 2006 May 1;24(13):1997-2005
pubmed: 16648500
J Minim Access Surg. 2021 Jul-Sep;17(3):342-350
pubmed: 32964887
Clin Nutr. 2003 Jun;22(3):321-36
pubmed: 12765673

Auteurs

Lucia Romano (L)

Department of Biotechnological and Applied Clinical Sciences, General Surgery, University of L'Aquila, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Antonio Giuliani (A)

Department of Biotechnological and Applied Clinical Sciences, General Surgery, University of L'Aquila, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Chiara Tomarelli (C)

Department of Biotechnological and Applied Clinical Sciences, General Surgery, University of L'Aquila, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Andrea Nervini (A)

Department of Biotechnological and Applied Clinical Sciences, General Surgery, University of L'Aquila, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Gianni Lazzarin (G)

Department of Biotechnological and Applied Clinical Sciences, General Surgery, University of L'Aquila, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Beatrice Pessia (B)

Hepato-biliopancreatic Surgery, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Vincenzo Vicentini (V)

Hepato-biliopancreatic Surgery, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Francesco Carlei (F)

Department of Biotechnological and Applied Clinical Sciences, General Surgery, University of L'Aquila, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Mario Schietroma (M)

Department of Biotechnological and Applied Clinical Sciences, General Surgery, University of L'Aquila, Department of Surgery, San Salvatore Hospital, L'Aquila, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH